Abstract: Tumor cells often have defects in DNA repair pathways that make them vulnerable to specific DNA-damaging anticancer agents. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer drugs are active areas of scientific investigation that may help rationalize and improve cancer chemotherapy. This article reviews the available data on the influence of defects in proteins involved in the major DNA repair pathways (i.e., homologous recombination, non-homologous end joining, base excision repair, nucleotide excision repair, mismatch repair, Fanconi anemia repair, translesion synthesis and direct reversal repair) on the cytotoxicity of the FDAapproved anticancer drugs. It is shown that specific deficiencies in these DNA repair pathways alter the cytotoxicity of 60 anticancer drugs, including classical DNA-targeting drugs (e.g., alkylating agents, cytotoxic antibiotics, DNA topoisomerase inhibitors and antimetabolites) and other drugs whose primary pharmacological target is not the DNA (e.g., antimitotic agents, hormonal and targeted therapies). This information may help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
INTRODUCTION
DNA is continually exposed to a variety of agents and processes (e.g., chemical carcinogens, ultraviolet and ionizing radiation, oxidative stress, and errors in DNA replication) that cause a range of DNA lesions (e.g., single-strand breaks, double-strand breaks, oxidative lesions, DNA adducts, and base mismatches, insertions and deletions). To preserve DNA integrity, cells have evolved mechanisms to detect DNA damage, signal its presence and mediate its repair. An intact DNA damage response (DDR) is vital to prevent genetic damage and the development of associated diseases such as cancer [1] [2] [3] .
Cancer is characterized by uncontrolled cell proliferation, in which genomic instability plays a crucial role. The genomic instability of cancer cells is probably the combined effect of DNA damage, DNA repair defects, and a failure to stop the cell cycle before the damaged DNA is transmitted to daughter cells. The importance of an intact DNA damage response to prevent the development of cancer is supported by the increased incidence of cancer observed in patients with specific human genetic diseases. For instance, people with Lynch syndrome, Ataxia telangiectasia, Bloom syndrome, Rothmund-Thomson syndrome, Werner syndrome, Fanconi anemia, and Xeroderma pigmentosum have particular DNA repair defects and are predisposed to develop specific types of cancer [3] [4] [5] [6] [7] .
Although an impared DNA damage response can drive genomic instability and the development of cancer, it can also provide therapeutic opportunities [1, 8] . Patients with inherited defects in DNA repair genes are hypersensitive to the anticancer effects of specific DNA-damaging compounds. For example, patients with Fanconi anemia have defects in the Fanconi anemia repair pathway and are hypersensitive to ionizing radiation and crosslinking drugs such as mitomycin C and cisplatin [9, 10] . In addition, most of the drugs currently used in the treatment of cancer are known to target the DNA of the cancer cells; examples of these drugs are alkylating agents, cytotoxic antibiotics, DNA topoisomerase poisons and antimetabolites. Although the basis for the selective anticancer activity of DNA-targeting drugs has been poorly understood for many years [11] , recent evidence suggests that the elevated levels of DNA damage in tumor cells and their inability to properly repair some types of DNA damage may explain why tumor cells are often more vulnerable than normal proliferating cells to specific DNA-targeting agents [12, 13] . For example, platinum compounds induce DNA lesions that are repaired by nucleotide excision repair (NER) and homologous recombination (HR). In contrast to nearly all metastatic cancers in adults, metastatic testicular germ-cell tumors can be cured with cisplatin-based combination chemotherapy, mainly because cells from these tumors are deficient in NER and therefore have a reduced capacity to repair cisplatin-induced DNA damage [14] . Unlike these tumor cells, normal proliferating cells (which have an intact NER pathway) would repair cisplatin-induced DNA damage and would survive treatment with this drug. Platinum compounds are also useful in high grade serous ovarian cancers, which commonly have deficiencies in HR repair (BRCA1 and BRCA2), and also improve survival in patients with non-small cell lung cancers defective in NER (ERCC1) [1] .
Until recently, cancers have been classified based on the anatomical site and histopathological features of the tumor, and treatment decisions have been made according to this classification. Given the impact that the DNA repair deficiencies of tumors can have on response to treatment, it seems reasonable to consider categorizing tumors according to their DNA repair defects and to use this information to personalize cancer treatments [1, 15] . The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer agents have become active areas of research. As a result, hundreds of reports assessing the influence of defects in DNA repair proteins on the cytotoxicity of a variety of anticancer drugs have been published in the last few years. The main purpose of this article is to compile the results of these reports. After providing a brief overview of the major DNA repair pathways, this article addresses whether specific defects in proteins involved in the major DNA repair pathways increase, reduce or do not change the cytotoxicity of the FDAapproved anticancer drugs. This information may provide a global view of how a defective DNA repair pathway modifies chemotherapy effectiveness, and may also help predict response to anticancer drugs in patients with tumors having specific DNA repair defects.
OVERVIEW OF DNA REPAIR PATHWAYS
The DDR machinery maintains genomic instability by detecting DNA damage, signaling its presence and mediating its repair. The DDR is a complex network that includes a set of DNA repair pathways, damage tolerance processes, and cellcycle checkpoint mechanisms. Because several excellent reviews have recently been published on the DDR, on DNA repair pathways and on the influence of these processes on cancer therapy [1, 2, [16] [17] [18] [19] [20] , this part of the article only seeks to provide a brief overview of the major DNA repair pathways.
Several major DNA repair pathways are known to participate in the repair of most types of DNA damage: homologous recombination (HR) repair, non-homologous end joining (NHEJ) repair, base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), Fanconi anaemia (FA) repair, translesion synthesis (TLS) and direct reversal repair (DRR). The choice of each of these pathways largely depends on the type of DNA damage that occurs; but other factors, such as the phase of the cell cycle, are known to play a role. Most of these pathways incorporate a similar set of tightly coordinated processes that include the detection of DNA damage, the accumulation of DNA repair factors at the site of damage and, finally, the physical repair of the lesion [1, 16] .
Homologous Recombination Repair
HR is a biological mechanism involved in the repair of DNA double-strand breaks (DSBs), DNA inter-strand cross links and damage encountered during DNA replication [21] . DSBs are lethal DNA damages caused by free radicals, some chemotherapeutic agents (e.g., etoposide) and ionizing radiation. After DNA damage, HR promotes accurate DNA repair by using an extended, undamaged homologous sequence as template. HR occurs during the late S and G 2 phases, when the damaged chromosome can enter into physical contact with its undamaged homologous DNA molecule (often the newly synthesized sister chromatid) which is used as template for repair [22] . HR is initiated by MRN complex (MRE11-RAD50-NBS1), which recognizes DSBs and resects them in the 5 ' 3' direction [5] . The result is the formation of a 3' single-stranded DNA fragment (ssDNA) which is immediately covered by RAD52 to protect it against nuclease attacks [5] . RAD52 then interacts with RAD51 and, with the help of other proteins (e.g., BRCA2, RAD54, XRCC2 and XRCC3), RAD51 forms a nucleoprotein filament on ssDNA and catalyzes homologous DNA pairing and strand exchange. After DNA synthesis, ligation and branch migration, the resulting structure is resolved [23] .
Non-Homologous End Joining Repair
NHEJ is also involved in the repair of DSBs. In contrast to HR, NHEJ ligates the two ends of a DSB without the requirement of a homologous template. NHEJ is errorprone, as sometimes this process can cause the deletion or mutation of nucleotides around the DSB site. NHEJ occurs throughout the cell cycle, but mainly in the G 0 /G 1 phases. The first step in NHEJ is the binding of Ku70/Ku80 heterodimer to the DSB. The Ku heterodimer then binds to the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and activates the XRCC4-ligase IV complex. This complex binds to the ends of DNA molecules and links together duplex DNA molecules with complementary but non-ligatable ends. Artemis, XLF, Polmu and Pollambda are other relevant proteins involved in NHEJ [5, 24] .
Base Excision Repair
The BER pathway repairs damaged bases (a single base or a short strand containing a damaged base), abasic sites and single strand breaks (SSBs). BER is initiated by a DNA glycosylase (e.g., MPG or OGG1) that recognizes the damaged base, removes it, and forms an abasic site in the DNA. Depending on the initial events in base removal, the repair is performed via short-patch (a single nucleotide is replaced) or long-patch (two to thirteen nucleotides are replaced) excision repair [5, 24, 25] . When the damaged base is removed by a glycosylase/lyase that cleaves the phosphodiester bond 3' to the abasic site, the repair is carried out through the short-patch BER pathway. The APEX1 endonuclease cleaves the 5' bond to the abasic site, generating a 1-nucleotide gap. The POLbeta fills in the 1-nucleotide gap and the XRCC1/ligase III complex executes strand ligation. When the damaged base is removed by a hydrolytic glycosylase (without lyase mechanism) or the abasic site is due to spontaneous hydrolysis, the repair is carried out through the long patch BER pathway. APEX1 cleaves the 5' phosphodiester bond to the abasic site, and the RFC/PCNA-POLdelta/epsilon complex displaces the strand 3' to the nick to synthesize a flap of 2-13 nucletoides, which is cleaved off by FEN1 endonuclease and is ligated by DNA ligase 1. Poly(ADP-ribose) polymerase (PARP) and XRCC1 are important components to recruit repair enzymes in both the short-patch and long-patch BER pathway.
Nucleotide Excision Repair
Whereas BER repairs small base damages, NER repairs some of the bulkier DNA lessions that distort the DNA helical structure, such as those induced by UV radiation and some mutagenic chemicals or chemotherapeutic drugs. NER can be divided into two sub-pathways: the global genome NER (GG-NER) and the transcriptioncoupled NER (TC-NER). GG-NER identifies and removes damages all over the genome whereas TC-NER repairs actively transcribed genes.
In GG-NER, the DNA lesion is recognized by the XPC/HR23B, RPA/XPA or DDB1/DDB2 complexes. In TC-NER, CS proteins (CSA and CSB) recognize DNA damage. The subsequent steps in both GG-NER and TC-NER are similar. Several factors, including transcription factor IIH (TFIIH), XPF, XPG and excision repair cross-complementing 1 (ERCC1), participate in the removal of a short singlestranded DNA segment (24-30 base pairs) containing the DNA lesion. The resulting gap in the DNA is filled by a DNA polymerase (i.e., POLdelta or POLepsilon), which uses the undamaged strand as a template, and is then ligated by DNA ligase III in complex with XRCC1 [16, 17] .
Mismatch Repair
Mismatch repair (MMR) plays an important role in maintaining genomic stability by repairing small insertions, deletions and base-base mismatches caused by spontaneous and induced base deamination, oxidation, methylation and replication errors [5, 24] . After DNA damage, the recognition of the lesion is performed by MutS complex (MSH2 and MSH6) or MutS complex (MSH2 and MSH3). The next step is the binding of MutL complex (MLH1 and PMS2) to MutS complex (or MutS complex). The DNA double strand is then cleaved and unwinded by a DNA helicase II, and the excision of the DNA strand containing the mispaired base is executed by exonuclease I. Finally, repair synthesis and ligation are carried out by DNA polymerase (POldelta) and DNA ligase I [16, 17] .
Fanconi Anaemia Repair (Interstrand Cross-Link Repair)
FA is a disorder characterized by chromosomal instability, bone marrow failure, cancer susceptibility, and a profound sensitivity to agents that produce DNA interstrand cross-links (ICLs). The FA pathway is thought to mediate the repair of ICLs at replication forks, possibly by facilitating ATR-and ATM-dependent checkpoint signaling and activating HR repair. The DNA damage response kinase ATR is recruited to single-stranded DNA at stalled replication fork structures. ATR activates the FA core complex, which is constituted by FANCA, FANCB, FANCE, FANCG, FANCL and FANCM. This complex monoubiquitinates FANCD2, which associates with proteins of other DNA repair pathways such as HR and TLS [26, 27] .
Translesion Synthesis
Translesion synthesis (TLS) is a eukaryotic DNA damage tolerance pathway that allows the replication of past DNA lesions (e.g., thymine dimmers or abasic sites), which may be induced by exposure to UV light or some chemical agents. One consequence of this process is the potential risk of introducing mutations [5] . During normal DNA replication, proliferating cell nuclear antigen (PCNA) stimulates replication by standard DNA polymerase. However, when replication is stalled as consequence of a DNA lesion, PCNA can be ubiquitinated by RAD6/RAD18 proteins and standard DNA polymerase can be replaced by a specialized polymerase (e.g., Polzeta, Polkappa and Poleta) that promotes lesion bypass and resumes DNA replication [5, 28] .
Direct Reversal Repair. O
6 -Methylguanine-DNA
Methyltransferase
The simplest solution that emerged in evolution to repair some types of DNA damage is the direct reversal of lesions by specialized enzymes, such as the suicide enzyme O 6 -methylguanine-DNA methyltransferase (MGMT).
Endogenous and external alkylating agents can transfer alkyl groups to guanine, thereby modifying the base and interfering with its pairing with cytosine during DNA replication. In human cells, that kind of lesions can be repaired in a single-step reaction by MGMT, which transfers the alkyl group from the alkylated guanine to an internal cysteine residue in its active centre. This reaction restore DNA to its intact state and leads to irreversible inactivation of MGMT [5, 17, 24] .
EFFECT OF DNA REPAIR DEFICIENCIES ON THE CYTOTOXICITY OF DRUGS USED IN CAN-CER THERAPY
The following section compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of the FDAapproved anticancer drugs. Data were identified by searches of PubMed, combining the name of each FDA-approved anticancer drug with the name of each DNA repair pathway and the most relevant proteins of the pathway. Reference lists of selected identified articles and of relevant reviews were also inspected. Only articles published in English were included.
Data are organized in tables, each of which shows results for a particular group of anticancer drugs. For each drug, data have been organized in DNA repair pathways (i.e., HR, NHEJ, BER, NER, MMR, FA, TLS and DRR), and the DNA repair proteins of each pathway have been arranged in alphabetical order. After the protein name, several symbols have been used to show how a deficiency in such protein modifies the cytotoxicity of the drug. When the DNA repair protein was absent in the cell (e.g., by knocking out the gene) the symbols +, -, or = have been used to show whether the absence of the protein increased (+), decreased (-) or did not change (=) the cytotoxicity of the drug. When the levels or activity of the protein were decreased in the cell (e.g., by changes in expression or chemical inhibition) the symbols , , or have been used to show whether the decreased levels Although this review article is focused on FDA-approved anticancer drugs, there are agents that have not yet reached mainstream clinical use and that should be mentioned to give a more complete picture of how the DNA repair defects of tumor cells can be exploited therapeutically. Some of these agents can work as sensitizers of specific FDAapproved DNA damaging agents and others can work as monotherapy by exploiting the concept of synthetic lethality [1, 2, 8] . PARP inhibitors are perhaps the best example to explain how the principle of synthetic lethality can be used to exploit the altered DDR of tumor cells and achieve selective cytotoxicity. PARP is required to repair DNA damage through the BER pathway. In the presence of PARP inhibitors (e.g. olaparib), the BER pathway would not repair damaged DNA bases, and formation of DSBs would occur during the S-phase of the cell cycle. Cells with a functional HR pathway would repair these DSBs and would survive treatment with PARP inhibitors. But when HR is dysfunctional, as occurs in BRCA1-or BRCA2-deficient cancers, cells would not repair the DNA damage and would not survive treatment with these agents. PARP inhibitors have already entered Phase III clinical trials [2, [29] [30] [31] [32] [33] [34] .
Alkylating Agents
Alkylating agents are among the oldest and most useful anticancer drugs. Their clinical use evolved from the observation of bone marrow suppression and lymph node shrinkage in soldiers exposed to mustard gas warfare during World War I. This large family of anticancer drugs works by inducing covalent bonds between highly reactive alkyl groups of the drugs (or of their active metabolites) and nucleophilic groups of nucleic acids and proteins (e.g., amine and sulfhydryl groups). The electrophilic properties of many of these drugs are mediated by the formation of carbonium ions (electron-deficient ions that react covalently with electron-rich groups, i.e., nucleophilic groups). The most common binding site for alkylating agents is the nitrogen atom of the amine group at position seven of the DNA base guanine. Many alkylating drugs have or generate two alkylating groups in their structure (bifunctional agents) and can induce crosslinking of DNA. These crosslinks may occur in the same strand (intrastrand crosslink) or in the opposite strands of the DNA (interstrand crosslink). Reactions between DNA and RNA, and between drug and proteins, may also occur. The most common mechanism by which these drugs initiate cancer cell death is covalent interaction with DNA, which alters DNA structure and function and causes inhibition of DNA replication, formation of DNA breaks and subsequent cell death. Although alkylating agents are not specific of any phase of the cell cycle, they are more active in rapidly dividing cells, probably because their DNA is more exposed than that of quiescent cells and because these cells also have less time to repair the DNA damage.
Alkylating agents are commonly classified in several groups: platinum compounds, nitrogen mustards, nitrosoureas, aziridines, and non-classical alkylating agents (agents whose chemical structure does not clearly reveal the alkylating function). Platinum compounds (cisplatin, carboplatin and oxaliplatin) are bifunctional drugs with a platinum atom responsible for their electrophilic properties. Nitrogen mustards (e.g., cyclophosphamide, iphosphamide and chlorambucil) have (or produce after metabolic activation) two chloroethyl groups responsible for their bifunctional alkylating activity.
Nitrosoureas used in cancer therapy (e.g., carmustine and lomustine) have in their structure one or two chloroethyl groups, a nitroso group (R-NO) and a urea group (two amine groups joined by a carbonyl functional group). Nitrosoureas alkylate and crosslink DNA, and also carbamoylate DNA and proteins. Like the nitrogen mustards cyclophosphamide and iphosphamide, the aziridine thiotepa is an organophosphorus compound. However, instead of having two chloroethyl groups in its structure, it has three aziridine groups (three-membered heterocycles with one amine group and two methylene groups) that mediate the alkylating properties of thiotepa. Like most alkylating agents, thiotepa crosslinks DNA and induces inhibition of DNA replication. The alkyl sulphonate busulfan appears to act through formation of carbonium ions, resulting in DNA alkylation. Dacarbazine and temozolamide are triazene (N-N=N) derivatives that cause methylation of DNA at the O6 and N7 positions of guanine. Procarbazine is a methylhydrazine derivative that appears to inhibit the trans-methylation of methionine into transfer RNA, thereby preventing protein synthesis. It may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through alkylation reactions. Other anticancer drugs (e.g., mitomycin C) have known alkylating properties but are not included in this section. This is because they also have other mechanisms of action or have traditionally been classified elsewhere (e.g., cytotoxic antibiotics). Table 1 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of the alkylating agents described above. Many results shown in this table are clearly in accordance with the mechanism of action of this group of drugs. Alkylating agents typically induce bulky DNA adducts that distort the DNA helical structure. Because this type of DNA damage is repaired by NER, cells with defects in most proteins involved in the NER pathway are hypersensitive to the cytotoxic activity of these drugs [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] . Many alkylating agents are bifunctional molecules that induce inter-strand crosslinks, which can be repaired by the FA pathway. It is not surprising, therefore, that cells defective in proteins of this pathway are hypersensitive to alkylating drugs [39, [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] . These drugs can also produce DSBs when DNA adducts are encountered by the DNA replication machinery. Since the HR pathway plays an important role in the repair of DNA inter-strand crosslinks and DSBs, cells with deficiencies in proteins involved in HR are typically hypersensitive to alkylating agents [36, 39, 48, 49, 52, 64, . DNA lesions induced by alkylating agents may stall DNA replication. Defects in proteins of the DNA damage tolerance pathway TLS make cells more vulnerable to all tested alkylating agents [28, 39, 64, [89] [90] [91] [92] [93] [94] [95] ; in this pathway, when replication is stalled as consequence of a DNA lesion, standard DNA polymerase is replaced by a specialized polymerase that promotes lesion bypass and resumes DNA replication.
No general conclusions can be drawn for the other DNA repair pathways. For instance, although the NHEJ pathway is involved in the repair of DSBs, defects in proteins of this pathway increase the cytotoxicity of some alkylating drugs (e.g., mechlorethamine [49, 96] ) but not of others (e.g., cisplatin [36, 39, 77, [97] [98] [99] ). The enzyme MGMT constitutes a DRR mechanism that can repair DNA damage induced by alkylating agents. This enzyme restores DNA integrity by transferring the alkyl group from an alkylated guanine to an internal cysteine residue in its active centre. Cells defective in MGMT are hypersensitive to some alkylating agents (e.g., nitrosoureas and dacarbazine [100] [101] [102] [103] [104] [105] [106] [107] [108] ) but not to others (e.g., cyclophosphamide and chlorambucil [101, 103, 106] ).
In patients, defects or decreased expression of proteins of some DNA repair pathways have been associated with a higher response to some alkylating agents. For instance, in patients with gliomas, inactivation of MGMT was associated with regression of the tumor and prolonged overall and disease-free survival of patients treated with the nitrosourea carmustine. Inactivation of MGMT was an independent and stronger prognostic factor than age, stage, tumor grade, or performance status [109] . MGMT deficiency also predicted the clinical response of primary gliomas to first-line chemotherapy with the alkylating agent temozolomide [110] . Absence or decreased levels of the NER protein ERCC1 has been associated with a high response to platinum-based chemotherapy of several types of cancer, including nonsmall-cell lung cancer, colorectal cancer, gastric cancer, testicular cancer and ovarian cancer [111] [112] [113] [114] [115] [116] . For instance, evidence suggests that the reduced levels of XPF-ERCC1 in testicular tumors can explain why cisplatin is particularly effective in treating this form of cancer [116] . Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug.
Defects in the HR protein BRCA1 have also been associated with a high response to platinum-based chemotherapy of lung and ovarian cancers [43, 117] .
Unlike other DNA repair pathways, Table 1 shows that cells with defects in proteins involved in MMR are resistant to the cytotoxic activity of several alkylating agents, including cisplatin, carboplatin, fotemustine, busulfan, dacarbazine, and procarbazine [100, [118] [119] [120] [121] [122] [123] [124] [125] [126] . The requirement of MMR for the cytotoxicity of some anticancer drugs has been explained by the "futile repair cycle" model. In this model, MMR removes the newly inserted intact base instead of the damaged base, triggering subsequent rounds of futile repair which can be toxic to the cell [18, 127] . Another explanation is that MMR proteins are also involved in mediating the acti-vation of cell cycle checkpoints and apoptosis in response to DNA damage and, therefore, loss of MMR may result in drug resistance by impairing the ability of the cell to detect DNA damage and activate apoptosis [128] . In other words, a functional MMR system seems to be required for the detection of DNA damage induced by some drugs. MMR proficient cells can detect such DNA damage and respond by inducing apoptosis. MRR deficient cells would not detect such DNA damage and would not activate apoptosis, therefore becoming resistant to these drugs. It is worth noting that cells deficient in MRR are resistant to cisplatin and carboplatin [118] [119] [120] [121] [122] [123] , but not to their analogue oxaliplatin [128, 129] , probably because MRR proteins recognize DNA adducts induced by cisplatin and carboplatin but not those induced by oxaliplatin [130] .
Antimetabolites
Antineoplastic antimetabolites comprise a large group of drugs that inhibit nucleic acid synthesis and induce the incorporation of altered nucleotides into the DNA or RNA. This group of drugs is known as antimetabolites because they have chemical structures similar to those of cellular metabolites involved in the synthesis of nucleic acids. Because of this chemical similarity, enzymes involved in nucleic acid synthesis react with these drugs instead of with their natural substrates, resulting in enzyme inhibition and subsequent inhibition of nucleic acid synthesis. Reaction of these drugs with the enzymes may also result in the synthesis of altered nucleotides that can be incorporated into the DNA or RNA, altering their structure and function. This group of drugs is specific for the S phase of the cell cycle.
Antimetabolites have been traditionally classified in three groups: antifolates (e.g., methotrexate and pemetrexed), pyrimidine analogs (e.g., fluorouracil, citarabine and gemcitabine) and purine analogs (e.g., mercaptopurine and thioguanine). Pyrimidine analogs are chemically related to the DNA bases cytosine, thymine and uracil (RNA), or to their nucleosides or nucleotides. Likewise, purine analogs share similar structures with the DNA bases adenine and guanine, or with their nucleosides or nucleotides. Folic acid, in the form of tetrahydrofolic acid, plays a critical role in nucleotide biosynthesis. The enzyme dihydrofolate reductase catalyzes the conversion of dihydrofolic acid into tetrahydrofolic acid and is the pharmacological target of the antifolate agent metotrexate. This drug binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Another representative example of how antimitabolites work is 5-fluorouracil (fluorouracil), which acts through a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP), which binds to and interferes with the activity of thymidylate synthase. This enzyme is required for synthesis of thymidine, one of the four essential building blocks of DNA. Another metabolite of 5-FU, the triphosphate nucleotide, is incorporated into RNA as an modified base and interferes with its function. Interference with both thymidine formation and RNA function is important in producing the cytotoxic effects of 5-FU. Although 5-FU nucleotides can also be incorporated directly into DNA and affect its stability, the contribution to cell death remains unclear. Another example is cytarabine (cytosine arabinoside), which has the sugar arabinose instead of ribose. Cytarabine is converted to the triphosphate form within the cell and then competes with the physiological nucleotide for incorporation into the DNA. Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication stops. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Gemcitabine is converted to the active metabolites difluorodeoxycytidine di-and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis. Thioguanine inhibits an enzyme involved in purine synthesis and also incorporates into DNA and RNA, resulting in inhibition of DNA and RNA synthesis and cell death. Table 2 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of antimetabolites. It shows that defects in proteins involved in HR generally make cells hypersensitive to the cytotoxicity of all tested antimetabolites (e.g., raltitrexed, 5-fluorouracil, cytarabine, 5-azacytidine, gemcitabine and 6-thioguanine [68, 69, [131] [132] [133] [134] [135] [136] [137] [138] ). The main cytotoxic mechanism of this group of drugs is inhibition of nucleotide synthesis. Depletion of nucleotides may initially result in stalled replication forks that, after prolonged treatment, collapse into DSBs that would be repaired by HR. Some antimetabolites (purine and pyrimidine analogues) may cause incorporation of nucleotides with altered bases into the DNA. Because damaged bases are repaired by BER, it is expected that cells deficient in BER are hypersensitive to these drugs. Table 2 shows, however, that defects in proteins of the BER pathway do not always increase the cytotoxicity of antimetabolites. For instance, depending on which protein of the BER pathway is defective, the cytotoxicity of gemcitabine and thioguanine (two antimetabolites known to cause incorporation of nucleotides with modified bases into the DNA) can increase or decrease [36, [139] [140] [141] [142] [143] [144] . Despite some exceptions [145, 146, 348] , NER deficiencies do not seem to play an important role in the cytotoxicity of purine and pyrimidine analogues [36, 133, 134, [147] [148] [149] , and MMR deficiencies generally decrease the cytotoxicity of antimetabolites [118, 119, [150] [151] [152] [153] [154] [155] [156] [157] . As mentioned before, MMR proteins are also involved in mediating the activation of cell cycle checkpoints and apoptosis in response to DNA damage and, therefore, loss of MMR may result in drug resistance by impairing the ability of the cell to detect DNA damage and activate apoptosis [128] . Although no general conclusions can be drawn for the other DNA repair pathways, defects in specific proteins can increase [62, 89, 134, [158] [159] [160] [161] or decrease [57] the cytototoxicity of these drugs. This information may help predict response to these drugs in patients with tumors having defects in such DNA repair proteins.
Cytotoxic Antibiotics
Cytotoxic antibiotics are a group of DNA-damaging anticancer drugs comprising natural products isolated from bacteria of the Streptomyces genus (e.g., doxorubicin, daunorubicin, dactinomycin, bleomycin and mitomycin C) and chemically related compounds obtained by synthesis, semisynthesis or biotechnology (e.g., idarubicin, epirubicin, valrubicin and mitoxantrone). These drugs intercalate into the DNA, induce topoisomerase II-mediated DNA damage and/or generate reactive oxygen species (ROS).
Some of these drugs are known as anthracyclines (e.g., doxorubicin, daunorubicin, idarubicin and epirubicin). Anthracyclines share a common, four-membered anthracene ring complex with an attached sugar moiety (the ring complex is a chromophore and accounts for the intense colors of these compounds). The cytotoxic activity of these drugs seems to be mediated by three different mechanisms. Anthracyclines intercalate between base pairs in the DNA helix, thereby altering its structure and function. They also interfere with DNA topoisomerase II activity, leading to the formation of topoisomerase II-mediated DNA damage. They also form ROS that can damage DNA and cell membranes, resulting in cytotoxicity (and side effects such as cardiotoxicity). Mitoxantrone is an anthracenedione synthesized in an attempt to develop agents with comparable antitumor activity to doxorubicin, but with an improved safety profile. Like the anthracyclines, mitoxantrone is an intercalating topoisomerase II poison, but with less potential ROS formation. Dactinomycin (actinomycin D) is a chromopeptide compound that intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via ROS formation. Bleomycin is a mixture of structurally related glycopeptide compounds isolated from Streptomyces verticillus. It forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single-and double-stranded breaks in the DNA. Mitomycin C is a methylazirinopyrroloindoledione that generates ROS, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. It also inhibits RNA and protein synthesis at high concentrations. Table 3 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of this group of anticancer agents. The most common mechanism of action of these drugs is production of DSBs, which may be mediated by topoisomerase II poisoning and/or formation of ROS. Because DSBs are repaired by HR and NHEJ, it is not surprising that defects in proteins involved in these pathways typically increase the cytotoxicity of all these drugs [39, 64, 71, 74, 96, 99, 142, . Defects in specific proteins involved in other DNA repair pathways can increase or decrease the cytototoxicity of these drugs. Like other alkylating agents that produce interstrand DNA cross-links, mitomycin C is more cytotoxic in cells defective in NER and FA [39, 53, 57, 172, [189] [190] [191] [192] [193] [194] [195] . Defects in these pathways do not typically modify the activity of other cytotoxic antibiotics that do not alkylate the DNA (e.g. doxorubicin and dactinomycin [57, 64, 163, [195] [196] [197] [198] [199] [200] ). A defective MMR pathway seems to decrease the cytotoxicity of some cytotoxic antibiotics (e.g. doxorubicin, epirubicin and bleomycin [201, 202] ), probably because loss of MMR may result in drug resistance by impairing the ability of the cell to detect DNA damage and activate apoptosis [128] . Defects in proteins involved in BER increase the cytotoxicity of bleomycin [203] [204] [205] [206] ; this drug induces oxidative damage and formation of SSBs, which are repaired by BER.
Topoisomerase Inhibitors
Topoisomerase inhibitors (also called topoisomerase poisons) comprise a group of anticancer drugs that cause DNA damage mediated by the enzymes DNA topoisomerase I or DNA topoisomerase II. These enzymes solve the topological problems associated with DNA replication, transcription, recombination and chromatin remodelling by introducing transient single-or double-strand breaks in the DNA. Topoisomerase poisons stabilize the normally transient topoisomerase-DNA complexes formed during the catalytic cycle of the enzyme; then, cellular processing converts these complexes into permanent DNA strand breaks that trigger cell death.
Topoisomerase inhibitors are classified into topoisomerase I inhibitors (topotecan and irinotecan) and topoisomerase II inhibitors (etoposide, teniposide and antracyclines). Irinotecan (a prodrug converted to the biologically active metabolite 7-ethyl-10-hydroxy-camptothecin: SN-38) and topotecan are semisynthetic derivatives of camptothecin (an alkaloid extracted from the bark of the Asian tree Camptotheca acuminate which was too toxic to be used in patients). Topoisomerase I poisons selectively inhibit topoisomerase I activity by stabilizing cleavable complexes between topoisomerase I and DNA. These drugs produce potentially lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Etoposide and teniposide are semisynthetic derivatives of podophyllotoxin, a botanical product extracted from the rhizome of the plant Podophyllum peltatum. They stabilise the normally transient topoisomerase II-DNA complexes formed during the catalytic cycle of the enzyme, resulting in inhibition of DNA strand religation and formation of cytotoxic single-and double-stranded breaks in the DNA.
The influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of topoisomerase inhibitors is shown in Table 4 . Although camptothecin is not approved for cancer therapy, it has been included in this review because its mechanism of action is similar to that of its derivatives topotecan and irinotecan, which have been less studied. Table 4 shows that cells with defects in most proteins involved in HR and NHEJ are hypersensitive to the cytotoxic activity of topoisomerase I and II inhibitors. Poisoning of topoisomerases I and II eventually produce DSBs when complexes are encountered by the DNA replication machinery. Since DSBs are repaired by HR and NHEJ, deficiencies in these pathways typically increase the cytotoxicity of topoisomerase poisons [71, 74, 97, 98, 133, 164, 165, 167, 174, 175, 186, 188, . Knowing that SSBs are repaired by BER, the ability of topoisomerase I poisons to produce SSBs may explain why cells deficient in proteins involved in BER are more sensitive than parental cells to Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug. FA: FANCA + [192, 193] ; FANCB + [192] ; FANCC + [39, 57, 192, 193] ; FANCD1 + [193, 194] ; FANCD2 + [194, 195] ; FANCE + [192] ; FANCF + [192, 193] ; FANCG + [57, 192, 193] ; FANCH + [192] .
DRR: MGMT = [105]
; MGMT - [106] .
TLS: POLkappa + [365]; RAD18 + [39]; REV3 + [39].
Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug. these drugs [228] [229] [230] [231] [232] [233] [234] . Defects in proteins involved in other DNA repair pathways can also modify the cytotoxicity of these drugs. For instance, deficiency in some proteins involved in the MMR pathway (e.g. MLH1 and MLH2) may decrease the cytotoxicity of etoposide, topotecan and irinotecan [118, 119, 201, 235] , probably because loss of MMR may result in drug resistance by limiting the ability of the cell to detect DNA damage and activate apoptosis [128, 201] .
Antimitotic Agents
Microtubule-targeting drugs (commonly known as antimitotic agents) are a group of naturally occurring compounds (e.g., vincristine, vinblastine and paclitaxel) and chemically related derivatives (e.g., vinorelbine and docetaxel) that bind to the protein tubulin and alter the normal balance between polymerization and depolymerization Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug.
of microtubules. This alteration in microtubule dynamics causes disruption of mitotic spindle assembly and arrest of cell division in the M phase of the cell cycle (mitosis).
These drugs have traditionally been classified into vinca alkaloids and taxanes. The term vinca alkaloid is used for bisindol alkaloids isolated from the plant Catharanthus roseus (formerly known as Vinca rosea) and for their semisynthetic or synthetic derivatives. Taxanes are a group of diterpene compounds with a taxane nucleus in their structure, some of which have anticancer activity (e.g., paclitaxel and docetaxel). Paclitaxel (taxol) was isolated from the bark of the Pacific yew tree, Taxus brevifolia; however, like docetaxel, it is now produced semisynthetically from compounds obtained from the needles of the European yew, Taxus baccata. Unlike the vinca alkaloids, which inhibit tubulin assembly, taxanes promote microtubule assembly and interfere with microtubule disassembly, resulting in formation of inappropriately stable, nonfunctional microtubules. Table 5 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of microtubule-targeting drugs. Although the DNA is not the pharmacological target of these drugs, data show that defects in specific DNA repair proteins may increase or decrease the cytotoxicity of these drugs. For example, cells deficient in NHEJ are hypersensitive to the cytotoxicity of the vinca alkaloid vincristine [174, 236] , glioma tumor xenografts defective in MMR are hypersensitive to vinorelbine [237] , and a decreased expression of BRCA2 mRNA (HR) was associated with a favorable response to docetaxel in breast cancer patients [238] . It is unclear why defects in some DNA repair proteins increase the cytotoxicity of microtubule-targeting drugs. The ability of some of these drugs to induce DNA damage [239, 240] , and the possible involvement of some DNA repair proteins in pathways that prevent cell death in response to these drugs, may play a role. On the other hand, cells lacking BRCA1 were highly resistant to the cytotoxicity of paclitaxel and vinorelbine; a functional BRCA1 may be required for an effective apoptotic response to these drugs [71] .
Hormonal and Targeted Therapies
Hormonal therapy inhibits the growth of hormonesensitive tumors (e.g., some breast, prostate and endometrial cancers) by reducing hormone production or by interfering with hormone action. Tamoxifen, a nonsteroidal selective estrogen receptor modulator (SERM), competitively inhibits the binding of the hormone estradiol to estrogen receptors in some tissues, thereby preventing estrogen action. The result is an inhibition of tumor growth in estrogensensitive tumors. Fulvestrant also causes antiestrogenic effects but, unlike tamoxifen (which has partial agonist effects in some tissues), fulvestrant is a pure antagonist of the estrogen receptor.
Some glucocorticoids (a class of steroid hormones) are also useful anticancer agents because of their antiinflammatory, immunomodulating and lymphotoxic effects. Their primary use is in the treatment of some hematologic malignancies (e.g., lymphomas, lymphocytic leukemias, and multiple myeloma). Prednisolone, prednisone and dexamethasone enter the nucleus where they bind to and activate specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production. They can also decrease the number of circulating lymphocytes, induce cell differentiation, and stimulate cell death in sensitive tumor cells populations.
Cancer-targeted therapies are therapies intended to target the molecular defects of cancer cells specifically. FDAapproved cancer-targeted therapies include drugs that interfere with cell growth signaling or tumor blood vessel formation, promote the specific death of cancer cells, stimulate the immune system to kill specific cancer cells, and deliver cytotoxic drugs to cancer cells. Many targeted therapies are included in the groups of protein kinase inhibitors (e.g., imatinib, erlotinib, sunitinib and gefitinib) or monoclonal antibodies (e.g., cetuximab). Erlotinib and cetuximab are examples of protein kinase inhibitors and monoclonal antibodies that induce anticancer effects by targeting the epidermal growth factor receptor (EGFR). Erlotinib binds to the intracellular catalytic domain of EGFR tyrosine kinase, thereby inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation. The monoclonal antibody cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization inhibits signal transduction and proliferative effects associated with EGFR activation. Table 6 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of hormonal and targeted therapies. Although the DNA is not the pharmacological target of these drugs, data show that defects in specific DNA repair proteins may increase or decrease the cytotoxicity of these drugs. For instance, chemical inhibition of the BER protein PARP increased the cytotoxicity of the anti-EGFR monoclonal antibody cetuximab [241] , and depletion of nuclear BRCA1 (HR) increased the cytotoxicity of the inhibitor of the EGFR tyrosine kinase erlotinib [242, 243] ; recent evidence suggests that both drugs can induce DNA damage [241, 242] . Defects in proteins of the NHEJ, BER and TLS pathways increased the cytotoxicity of the antiestrogenic drug tamoxifen [244, 245] , which can also induce DNA damage [244, [246] [247] [248] . Deficiencies in the HR protein BRCA1, however, decreased the cytotoxicity of the antiestrogens tamoxifen and fulvestrant [249, 250] ; this effect may be associated with a low estrogen receptor expression in BRCA1-mutant tumors [250] .
Other Anticancer Drugs
This section includes drugs with mechanisms of action different from those of other groups of drugs discussed before. Bortezomib is a dipeptide boronic acid analogue that induces anticancer effects by inhibiting the proteasome (proteasomes are protein complexes within cells that are responsible for degrading and eliminating cellular proteins, some of which regulate critical functions for successful cancer growth). Inhibition of proteasome by bortezomib results in disruption of several cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Some NHEJ: DNA-PKcs - [98] .
MMR: MLH1 = [201]; MSH2 = [201].
Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug. 
Monoclonal antibodies
Cetuximab BER: PARP [241] .
Symbols +, -, or = show whether the absence of a protein increases (+), decreases (-) or does not change (=) the cytotoxicity of the drug. Symbols , , or show whether the decreased levels or activity of a protein increase ( ), decrease ( ) or do not change ( ) the cytotoxicity of the drug.
leukemic cells cannot synthesize the amino acid Lasparagine de novo due to the absent or deficient expression of the enzyme asparagine synthase. L-asparaginase is an enzyme with antileukemic activity that degrades the amino acid L-asparagine, resulting in the depletion of L-asparagine, inhibition of protein synthesis, cell cycle arrest in the G1 phase, and apoptosis in susceptible leukemic cells. Hydroxyurea inhibits the enzyme ribonucleoside diphosphate reductase, which is required to convert ribonucleotides into the deoxyribonucleotide forms required for both DNA synthesis and repair. Cells accumulate in the S phase because DNA synthesis is inhibited, and only abnormally short DNA strands are produced. Arsenic trioxide is an effective treatment for acute promyelocytic leukemia, probably because of its ability to induce apoptosis, promote cell differentiation and suppress cell proliferation. Trabectedin is a tetrahydroisoquinoline alkaloid isolated from the marine organism Ecteinascidia turbinate. It binds to the minor groove of DNA, interferes with the DNA repair machinery and induces lethal DNA strand breaks. Thalidomide (a drug that caused severe limb deformities when used by pregnant women as an overthe-counter sedative in the 1960s) has a complex cytotoxic mechanism of action. It is a glutamic acid derivative that inhibits angiogenesis, induces free-radical oxidative damage to DNA, interferes with adhesion of cancer cells, inhibits tumor necrosis factor-production, and alters secretion of cytokines that affect the growth of cancer cells. Vorinostat is a synthetic hydroxamic acid derivative that inhibits histone deacetylases, which causes accumulation of both hyperacetylated histones and transcription factors and leads to antiproliferative effects and apoptosis. Tretinoin is a naturallyoccurring acid of retinol that binds to and activates retinoic acid receptors, thereby inducing changes in gene expression that lead to cell differentiation and decreased cell proliferation. 5-aza-2'-deoxycytidine (decitabine) incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and arrest of DNA replication. Table 7 compiles data from reports assessing the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity of these drugs. Trabectedin is the only drug from this group whose mechanism of action involves DNA damage. Since trabectedin interferes with the transcription-coupled NER machinery to induce lethal DNA strand breaks and cell death, cells with defects in proteins of this pathway (e.g., CSA, CSB, ERCC1, XPA, XPB, XPD, XPF and XPG) [251] [252] [253] [254] [255] , but not in those specific of the global genomic NER pathway (e.g., XPC) [255] , are resistant to the cytotoxicity of trabectedin. Poisoning of the enzyme topoisomerase I by trabectedin [256] may produce potentially lethal DSBs when complexes are encountered by the DNA replication machinery. Because DSBs are repaired by HR and NHEJ, a deficient HR pathway and deficiencies in some proteins of the NHEJ pathway increase the cytotoxicity of trabectedin [251, 252, 257] . This drug produces DNA modifications similar to interstrand crosslinks [258] , which may explain why cells defective in FA (involved in interstrand crosslinks repair) are hypersensitive to trabectedin [193] . The influence of defects in DNA repair proteins on the cytotoxicity of hydroxyurea has been evaluated in numerous studies. Hydroxyurea inhibits the enzyme required to convert ribonucleotides into deoxyribonucleotides, which are necessary for both DNA synthesis and repair. Although hydroxyurea has a mechanism of action similar to that of antimetabolites, this drug has not been classified in the antimetabolites group becaused it cannot be included into any of the three subgroups in which antimetabolites are typically classified (antifolates, purine analogs and pyrimidine analogues). Evidence suggests that depletion of nucleotides by this drug may initially result in stalled replication forks that, after prolonged treatment, collapse into DSBs [259] . Since DSBs are repaired by HR and NHEJ, deficiencies in these pathways should increase the cytotoxicity of hydroxyurea. However, although deficiencies of some proteins of these pathways increase the cytotoxicity of hydroxyurea [68, 188, 227, 260- FA: FANCA + [193] ; FANCC + [193] ; FANCD1 + [193] ; FANCF + [193] ; FANCG + [193] .
Thalidomide NER: CUL4A [276] .
Tretinoin BER: APEX1 [271] ; PARP [272] .
5-Aza-2'-deoxycytidine
265], deficiencies of other proteins do not change its activity or even reduce it [68, 165, 188, 227, 262] . Deficiencies in the BER, MMR and DRR pathways seem to increase the cytotoxicity of hydroxyurea [158, 235, 266] , and defects in NER, FA and TLS do not seem to have a marked effect in its cytotoxicity [267] [268] [269] . With regard to the other drugs compiled in Table 7 , deficiencies in BER increase the cytotoxicity of bortezomib and tretitoin [270] [271] [272] and decrease that of L-asparaginase [273] , deficiencies in NER increase the cytotoxicity of arsenic trioxide [274, 275] but decrease that of thalidomide [276] , and deficiencies in MMR do not modify the cytotoxicity of L-asparaginase and vorinostat [277, 278] .
Results collected in Tables 1-7 have also been organized in Fig. (1) and Fig. (2) , which show all FDA-approved anticancer drugs whose cytotoxicity is increased in cells lacking a particular DNA repair protein. References are not shown in these figures for simplicity (they can be accessed from Tables 1-7). These figures may help decide which FDAapproved anticancer drugs may induce a higher cytotoxic effect in tumor cells with defects in a particular DNA repair protein. Table 8 also remarks the most significant findings compiled in Tables 1-7 ; it shows all FDA-approved anticancer drugs (in alphabetical order) whose cytotoxic activity is increased or decreased in the absence of particular DNA repair proteins. 
CONCLUSION
Tumor cells commonly have DNA repair deficiencies that can profoundly alter the efficacy of chemotherapy. The identification of DNA repair defects in tumor cells and the evaluation of their influence on the cytotoxicity of anticancer agents have become active areas of research. Much information has become available in recent years on the influence of defects in proteins involved in the major DNA repair pathways on the cytotoxicity numerous anticancer drugs. This information has been reviewed for the first time in this article and several conclusions can be made.
The first conclusion is that deficiencies in proteins involved in DNA repair pathways alter the cytotoxicity of numerous FDA-approved anticancer drugs. Data were available for 65 drugs used in cancer therapy, and the cytotoxicity of 60 of them was altered in cells deficient in specific DNA repair proteins. The cytotoxicity of the remaining 5 drugs (i.e., iphosphamide, daunorubicin, teniposide, dexamethasone and vorinostat) was not altered in cells deficient in particular DNA repair proteins. In the case of the DNA-damaging drugs iphosphamide, daunorubicin and teniposide, this is probably because the influence of relevant DNA repair proteins has not yet been evaluated. It is also worth noting that deficiencies in proteins involved in DNA repair pathways can not only alter the cytotoxicity of drugs that target the DNA, but also that of drugs whose primary pharmacological target is not the DNA. This may be explained by the ability of these latter to induce DNA damage (which may play a role in their cytotoxicity), or by the involvement of some DNA repair proteins in survival or apoptotic pathways triggered by these drugs.
XRCC3
5-Azacytidine, camptothecin, cisplatin, cytarabine, doxorubicin, hydroxyurea, mechlorethamine, melphalan, mitomycin C, topotecan and trabectedin
XRCC2
Camptothecin, cisplatin, fotemustine, hydroxyurea, mechlorethamine, melphalan, mitomycin C, nimustine, temozolomide, topotecan and trabectedin
RAD51B

Cisplatin
RAD51C
Bleomycin, camptothecin, cisplatin, etoposide, idarubicin, mitomycin C and trabectedin
RAD51D
5-Azacytidine, 6-thioguanine, chlorambucil and cisplatin 
BRCA2
DNA-PKcs
Bleomycin, doxorubicin, hydroxyurea, idarubicin, mechlorethamine, melphalan and temozolomide
NHEJ FANCF
Bleomycin, cisplatin, mitomycin C and trabectedin
FANCE
Bleomycin and mitomycin C 
MLH1
Hydroxyurea and raltitrexed
MSH2
Cytarabine, lomustine, methotrexate, mitomycin C, raltitrexed and vinorelbine
PMS2
Mitomycin C
MSH3
Cisplatin and oxaliplatin Deficiencies in particular DNA repair proteins and pathways can alter the cytotoxicity of related drugs differently. It is not completely accurate, therefore, to generalize and say that deficiencies in a specific DNA repair pathway modify the cytotoxicity of a particular group of anticancer drugs. Although some general conclusion can be made in this regard (discussed in section 3), results can substantially change when a specific protein of the pathway or a particular drug of the group are studied. For instance, it is common to find in the literature that deficiencies in the NER pathway or in the protein MGMT (DRR) increase the cytotoxicity of alkylating agents. Although this is true for many alkylating drugs, data show that cells defective in the NER protein CSB are resistant to the alkylating drug mechlorethamine [49] , or that deficiencies in the protein MGMT do not change the cytotoxicity of the alkylating agents cyclophosphamide or melphalan [101, 103, 106] . Knowing that tumors commonly have deficiencies in particular proteins and that patients are treated with specific drugs, it seems sensible to avoid generalizations and always specify both the protein and the drug.
CSA
The information compiled in this article may help understand the cytotoxic mechanism of some drugs. For instance, although the main cytotoxic mechanism of antimetabolites is inhibition of nucleotide synthesis, it is not clear how this inhibition triggers cell death. Table 2 shows that defects in proteins involved in HR typically make cells hypersensitive to the cytotoxicity of all tested antimetabolites [68, 69, [131] [132] [133] [134] [135] [136] [137] [138] , thereby suggesting that the formation of DSBs (repaired by HR) plays an important role in the anticancer activity of these drugs. Depletion of nucleotides induced by antimetabolites may initially result in stalled replication forks, which may eventually collapse into DSBs that trigger cell death.
Because the DNA repair deficiencies of tumors can have a significant impact on patient response to treatment, researchers are beginning to consider classifying tumors according to their DNA repair defects and to use this information for cancer treatment decisions. The use of DNA repair gene profiles and the identification of molecular and functional DNA repair biomarkers will provide useful data for this purpose [1, 15] . Information on the influence of particular DNA repair defects on the cytotoxicity of the existing anticancer drugs will also be essential for cancer treatment decisions. This article has compiled this information and shows whether specific defects in proteins involved in the major DNA repair pathways increase, reduce or do not change the cytotoxicity of the FDAapproved anticancer drugs. This information may help predict response to anticancer drugs in patients with tumors with specific DNA repair defects, which would improve the efficacy of their treatments. 
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